Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Amy Weinberg, DNP, MS

Senior Director
Gilead Sciences, Inc.

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Private Company)

Poster(s):

(P-473) Health Care Resource Use Burden Among People With HIV (PWH) and Concurrent Mental Health Disorders (MHDs): Claims Analysis of Treatment-Naïve Medicaid Population Initiating Multi-Tablet Regimens (MTRs) vs. Single-Table Regimens (STRs)

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-529) Comparison of Renal Outcomes by Tenofovir Alafenamide Fumarate (TAF) vs. Tenofovir Disoproxil Fumarate (TDF) Containing Regimens for Prevention, and Treatment of HIV and/or HBV Treatment: A Systematic Literature Review and Meta-Analysis

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-547) Efficacy and Safety of B/F/TAF in Treatment-Naïve People With HIV Aged ≥ 50 Years: 5-Year Follow-Up From Two Phase 3 Studies

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-581) Racial/Ethnic Disparities of Renal Outcomes in People with HIV (PWH) on Tenofovir Alafenamide (TAF) Based Antiretroviral Treatment (ART) Regimens in the Real World

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT